Forex Daily Forecast, Analysis and Prediction

The price begins to recover from a 3-month low as the US Dollar starts to show some weakness.

AUD/USD steadied after US data and court headlines, but a bearish head-and-shoulders pattern signals potential breakdown toward 0.6400.

BTC/USD rebounded to $104K after hitting key support, but with bearish momentum still in play, a retest of $98,950 remains likely unless bulls reclaim $106,800.

GBP/USD formed a bearish double-top and dropped ahead of the BoE decision and UK tax hike signals, with further downside likely if support at 1.2940 breaks.

EUR/USD continued its slide below 1.1500, with bearish momentum intact and technical indicators nearing oversold levels ahead of key Eurozone and US data.

Gold fell below the $4,000 mark amid renewed US dollar strength and rising yields, with traders watching support at $3930 and resistance near $4110.

USD/BRL edged higher near key resistance at 5.40, with traders watching for a breakout toward 5.4685 or a reversal as global market volatility rises.

USD/ZAR surged toward 17.58 before pulling back slightly, with traders eyeing key resistance at 17.4750 as market volatility and Fed uncertainty persist.

The US dollar rebounded against the Swiss franc, hinting at a potential breakout as SNB intervention risks and broader dollar strength drive bullish momentum.

The S&P 500 bounced after testing support at 6,800, with bullish momentum pointing toward a move back to 7,000 as year-end optimism builds.

The NASDAQ 100 dipped in premarket trading but held above key support at 25,500, with bulls targeting 26,000 as year-end momentum builds.

The British pound extended its decline below 1.31 on Tuesday, with bearish momentum pointing toward 1.2750 amid rising rate-cut expectations.

USD/CAD extended its rally on Tuesday, supported by rate differentials and soft oil prices, with bulls eyeing a move toward the 1.4250 resistance level.

Decreased full-year guidance, margin pressure, and high valuations overshadow a strong immunology growth rate. How did earnings impact AbbVie’s outlook?

A massive earnings beat sent shares rallying, but the latest GLP-1 treatment underperformed, while long-term debt is rising and profit margins are shrinking. Did earnings justify the rally in Eli Lilly?